News | July 22, 2014

SCAI Publishes Expert Consensus Recommendations for Treating Below-the-Knee Peripheral Artery Disease

July 22, 2014 -- The incidences of obesity and diabetes are increasing, and with them the number of patients with peripheral artery disease (PAD) in the arteries of the limbs. A new series of expert consensus recommendations developed by the Society for Cardiovascular Angiography and Interventions (SCAI) will help physicians determine the best course of action for patients whose blockages reduce blood flow to their limbs, putting them at risk for gangrene and amputation. The third paper in the series, e-published in Catheterization and Cardiovascular Interventions, outlines recommendations for treating infrapopliteal (IP), or “below-the-knee,” arterial disease.
 
Elderly patients and those with long-standing diabetes or chronic kidney disease are at greatest risk of developing such blockages, which can progress to critical limb ischemia (CLI), a painful and chronic condition that can lead to amputation. As the population ages and the number of patients with diabetes rises, the rate of CLI is expected to increase.
 
“Treating patients with IP arterial disease and CLI can relieve pain, heal ulcerations, preserve limbs and improve quality of life and function,” said Bruce H. Gray, D.O., FSCAI, professor of surgery/vascular medicine, University of South Carolina School of Medicine, and lead author of the consensus paper. “Depending on the patient’s condition, open surgery, an endovascular intervention or amputation are considered appropriate courses of action. These new recommendations aim to help guide physicians to make the best care decisions when an endovascular approach is appropriate.” 
 
The expert panel reviewed scientific data on each CLI treatment option, including balloon angioplasty, stents, atherectomy, as well as experimental therapies such as drug-coated balloons.Patients with severe disease, those with pain at rest and those with minor or major tissue loss should be considered for revascularization, with either surgery or endovascular treatment to prevent amputation or improve healing following amputation. Currently there is insufficient evidence to support treatment in those with asymptomatic disease.This document is the latest in SCAI’s series of recommendations for treating PAD. Previous documents included “SCAI Expert Consensus Document for Aorto-Iliac Arterial Intervention Appropriate Use” and “SCAI Expert Consensus Document for Femoral-Popliteal Arterial Intervention Appropriate Use.” The final document in the series will focus on renal artery stenosis and will be published in Catheterization and Cardiovascular Interventions later this summer.
 
“SCAI is committed to providing physicians with the necessary tools to appropriately diagnose and treat patients,” said SCAI 2014-15 President Charles Chambers, M.D., FSCAI. “These recommendations were developed based on our belief that patient safety and quality should always be physicians’ top priority.” The paper, titled “SCAI Expert Consensus Statement for Infrapopliteal Arterial Intervention Appropriate Use,” is e-published in Catheterization and Cardiovascular Interventions.
 
For more information: www.SCAI.org

Related Content

Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init